Q3 Earnings Forecast for SLDB Issued By Leerink Partnrs

Key Points

• Leerink Partners raised their Q3 2025 earnings per share estimate for Solid Biosciences to ($0.43), an improvement from a prior estimate of ($0.60).
• Solid Biosciences reported a quarterly EPS of ($0.42), exceeding analysts' expectations of ($0.51).
• A majority of market analysts have a buy rating on Solid Biosciences, with an average price target of $15.00 per share.

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Investment analysts at Leerink Partnrs increased their Q3 2025 earnings per share (EPS) estimates for Solid Biosciences in a research note issued on Wednesday, August 13th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings of ($0.43) per share for the quarter, up from their prior forecast of ($0.60). The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share. Leerink Partnrs also issued estimates for Solid Biosciences' Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.85) EPS and FY2026 earnings at ($1.92) EPS.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.42) earnings per share for the quarter, topping analysts' consensus estimates of ($0.51) by $0.09.

SLDB has been the subject of a number of other reports. JMP Securities reaffirmed a "market outperform" rating and set a $15.00 price objective on shares of Solid Biosciences in a research note on Friday, June 6th. Wall Street Zen upgraded Solid Biosciences from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. JPMorgan Chase & Co. dropped their target price on Solid Biosciences from $15.00 to $13.00 and set an "overweight" rating on the stock in a report on Thursday, August 14th. HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Solid Biosciences in a research note on Tuesday, June 17th. Finally, Citigroup started coverage on Solid Biosciences in a research note on Thursday, June 26th. They issued a "buy" rating and a $14.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and ten have issued a Buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $15.00.

Solid Biosciences Stock Up 4.8%

Shares of Solid Biosciences stock traded up $0.27 during trading on Monday, reaching $5.93. 794,407 shares of the company were exchanged, compared to its average volume of 1,162,857. Solid Biosciences has a twelve month low of $2.41 and a twelve month high of $10.07. The business has a 50-day moving average price of $5.74 and a 200-day moving average price of $4.52. The firm has a market capitalization of $461.77 million, a price-to-earnings ratio of -2.12 and a beta of 2.44.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Legal & General Group Plc raised its position in Solid Biosciences by 208.6% during the 2nd quarter. Legal & General Group Plc now owns 6,011 shares of the company's stock worth $29,000 after purchasing an additional 4,063 shares during the last quarter. Ameritas Investment Partners Inc. grew its stake in shares of Solid Biosciences by 205.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company's stock valued at $33,000 after buying an additional 4,534 shares during the period. CWM LLC grew its stake in shares of Solid Biosciences by 15,188.5% in the 1st quarter. CWM LLC now owns 7,950 shares of the company's stock valued at $29,000 after buying an additional 7,898 shares during the period. Corton Capital Inc. acquired a new position in Solid Biosciences during the 4th quarter valued at about $41,000. Finally, Pallas Capital Advisors LLC acquired a new position in Solid Biosciences during the 2nd quarter valued at about $54,000. 81.46% of the stock is currently owned by institutional investors.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.